Protein biosynthesis, a target of sorafenib, interferes with the unfolded protein response (UPR) and ferroptosis in hepatocellular carcinoma cells

Sorafenib is the first line treatment for advanced hepatocellular carcinoma (HCC). We explored its impact on the proteostasis of cancer cells, i.e. the processes that regulate the synthesis, maturation and turn-over of cellular proteins. We observed that sorafenib inhibits the production of the tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauzay, Chloé, Louandre, Christophe, Bodeau, Sandra, Anglade, Frédéric, Godin, Corinne, Saidak, Zuzana, Fontaine, Jean-Xavier, Usureau, Cédric, Martin, Nathalie, Molinie, Roland, Pascal, Julie, Mesnard, François, Pluquet, Olivier, Galmiche, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823558/
https://www.ncbi.nlm.nih.gov/pubmed/29492203
http://dx.doi.org/10.18632/oncotarget.23843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5823558/
https://www.ncbi.nlm.nih.gov/pubmed/29492203
http://dx.doi.org/10.18632/oncotarget.23843

Ejemplares similares